



Resolution n°8-2023-e

Extension of authorization to procure COVID-19 therapeutics, with reallocation of unspent ACT-A funds to Unitaid's Medical Oxygen Portfolio

Recalling Resolution R3-2022-e of 11 February 2022, through which the Executive Board authorized the Executive Director to commit up to a further US\$ 22,000,000 (twenty-two million dollars) to the five Unitaid projects named in that decision, in order to fund the procurement and allocation to those projects of newly recommended and pipeline COVID-19 therapeutic products, on condition that the orders would be placed within 12-months of that decision;

Acknowledging that it has ultimately not been necessary for Unitaid to procure the volumes of COVID-19 therapeutics foreseen at the time of the adoption of Resolution R3-2022-e and the Executive Director has therefore committed only US\$ 700,000 (seven hundred thousand dollars) of the funds available under that decision; and

Acknowledging the importance of continuing to support limited procurement of targeted novel antiviral and ancillary product in accordance with Resolution R3-2022-e, in line with the recommendations of the Secretariat, the Executive Board hereby further extends the duration of the authorization provided in Resolution R5-2020-e to 31 December 2023. The total value of any further procurement orders placed under this decision shall not exceed US\$ 600,000 (six hundred thousand dollars).

The Board also authorizes the Executive Director to extend the duration of the COVID-19 related outputs of the five Unitaid projects concerned (as named in Resolution R3-2022-e), up to 31 December 2023, subject to the signature of an amendment to the legal agreements between Unitaid and each of the lead implementers of the five projects.

Underlining, in addition, the importance of Unitaid's work in medical oxygen, the Board also hereby releases and reallocates US\$ 4,400,000 from the balance of unspent ACT-A funds previously committed under Resolution R3-2022-e. The released funds shall be available for commitment to the Medical Oxygen Portfolio, in line with applicable Board decisions or authorizations to be provided separately.

Marisol Touraine
Chair of the Unitaid Executive Board

Date: 20 June 2023